Literature DB >> 10718850

Exposure and allergic sensitization to cockroach allergen in East Germany.

T Hirsch1, C Stappenbeck, V Neumeister, S K Weiland, E Von Mutius, U Keil, W Leupold.   

Abstract

BACKGROUND: Some studies suggest that the prevalence of sensitization to cockroach allergens may be higher in the United States than in Europe, but there are no comparable data from population-based studies.
OBJECTIVES: To determine the prevalence of allergic sensitization to German cockroach (GCR) in German schoolchildren and to assess its clinical relevance; and to determine the exposure to the major GCR allergen Bla g 2 in non-selected homes and nurseries.
METHODS: The prevalence of allergic sensitization to GCR and other allergens was determined by measurement of specific IgE and skin-prick tests in a cross-sectional study of 2993 children aged 5-11 years in Dresden, Germany. The prevalence of atopic disease was determined by questionnaire, and pulmonary function and bronchial hyperresponsiveness to hypertonic saline were measured. Bla g 2 exposure was determined on floors of 187 kitchens and 47 nurseries by a commercial sandwich ELISA.
RESULTS: One hundred and twenty-seven (4.2%) of the children had specific IgE (> 0.7 kU/L) against GCR. Among children with current wheeze, 8.4% were GCR-sensitized. Compared to data from the United States, the prevalence of sensitization to cockroach was similar in children without asthma (3.9%), but less frequent in asthmatic children from Dresden (6.1%). After adjustment for positive reactions to other allergens (SX1 test) no significant impact of GCR sensitization on wheeze or other symptoms and diagnoses was found. Bla g 2 was detected in 29% of the kitchens and 43% of the nurseries. None of these sites had exposure levels above the proposed threshold for causing disease of 80 ng/g dust.
CONCLUSION: The data suggest that allergic sensitization to GCR is less frequent in asthmatics from Dresden, Germany than in US cities. The data indicate that GCR sensitization is not an independent risk factor for asthma and other atopic diseases in 5-11-year-olds from this city.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718850     DOI: 10.1046/j.1365-2222.2000.00785.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  7 in total

1.  Cockroach sensitisation in Belgian children.

Authors:  Dirk Van Gysel; Elke Govaere; Erenik Doli; Frans De Baets
Journal:  Eur J Pediatr       Date:  2006-04-19       Impact factor: 3.183

2.  Occupational health risks due to shipboard cockroaches.

Authors:  Marcus Oldenburg; Ute Latza; Xaver Baur
Journal:  Int Arch Occup Environ Health       Date:  2007-09-25       Impact factor: 3.015

3.  Messages from the Aalst Allergy Study.

Authors:  Dirk Van Gysel; Elke Govaere; Katia M C Verhamme; Erenik Doli; Frans De Baets
Journal:  World J Pediatr       Date:  2009-08-20       Impact factor: 2.764

Review 4.  [Aeroallergens becoming more significant for allergic rhinitis].

Authors:  C Rudack; F Sachse; S Jörg
Journal:  HNO       Date:  2003-09       Impact factor: 1.284

Review 5.  Environmental exposures and asthma morbidity in children living in urban neighborhoods.

Authors:  E C Matsui
Journal:  Allergy       Date:  2014-02-20       Impact factor: 13.146

Review 6.  Cockroach, tick, storage mite and other arthropod allergies: Where do we stand with molecular allergy diagnostics?: Part 15 of the Series Molecular Allergology.

Authors:  Christiane Hilger; Annette Kuehn; Monika Raulf; Thilo Jakob
Journal:  Allergo J Int       Date:  2014-09-29

7.  Exposure to Indoor Allergens in Different Residential Settings and Its Influence on IgE Sensitization in a Geographically Confined Austrian Cohort.

Authors:  Teresa Stemeseder; Bettina Schweidler; Patrick Doppler; Eva Klinglmayr; Stephanie Moser; Lisa Lueftenegger; Martin Himly; Roland Lang; Joerg Zumbach; Gertie J Oostingh; Thomas Hawranek; Arne C Bathke; Gabriele Gadermaier
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.